Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Gastrointestinal Neoplasms 1EGFR-Mutated Non-Small-Cell Lung Carcinoma 1Colonic Neoplasms 1Carcinoma 1Burkitt Lymphoma 1

Interventions

olaparib 1durvalumab 1Electrocardiography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × EGFR-Mutated Non-Small-Cell Lung Carcinoma × Electrocardiography × Clear all
NCT04538378 2025-01-27

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 11 charts
EndocrineThoracic

EGFR-Mutated Non-Small-Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡